Dorrapharma is a comprehensive pharmaceutical group integrating R&D, manufacture and sales of pharmaceutical APIs and intermediates, cosmetic ingredients, veterinary drug ingredients, formulations and etc. We own the core technology advantage in the area of bromination, enzyme/metalcatalyzed, nitration and hydrogenation, and obtain multiple core patents for invention. We stick to raising the value both for the company and customers...
MORE
At present, Dorra has two R&D centers, Nanjing R&D Center and Taizhou R&D Center, which are located in Nanjing Jiangbei New District, the first national new district in Jiangsu Province, New Materials Life Science Park, and Taizhou City, Zhejiang Province, with a total area of 6000 square meters...
Dorra Pharma currently has three production bases which are located at the Grade D industrial Park in Hubei and Gansu Province with total reactor capacity of 3,000 m3. The quality system are approved by NMPA/PMDA/US FDA, offering key starting material, GMP intermediates, APIs and CDMO services.
MORE
On February 26, 2026, The U.S. Food and Drug Administration (FDA) has approved Dupixent (d...
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
